ST-920

ESGCT 2022 – Sangamo strengthens its case in Fabry
EP Vantage
Thu, 10/13/22 - 09:11 am
Sangamo BioSciences
Fabry disease
ESGCT
ST-920
Sangamo's Fabry gene therapy clears early clinical test, firing starting gun on preparations for phase 3
Fierce Biotech
Thu, 11/4/21 - 10:48 am
Sangamo Therapeutics
Fabry disease
gene therapy
clinical trials
ST-920